This database includes English name, structural formula, molecular formula and molecular mass, chemical name and CAS registry number of "the Japanese Pharmacopoeia".
Cosmetics ingredients / By product name｜ICHIMARU PHARCOS
Cosmetic ingredients of ICHIMARU PHARCOS by product name.
Ingredient Database | Deep-Researched Cosmetic Ingredients | Roots by Benda
Deep-researched cosmetic ingredient database — MoS calculations, SCCS citations, dermal absorption, sensitization data. Multi-jurisdiction regulatory status.
Cassava Sciences: Of stocks and blots
A group of anonymous persons filed a Statement of Concern with the FDA regarding the integrity of research papers about Simufilam, an Alzheimer’s Disease treatment drug candidate developed by…
lexidex
This is a web index of atproto data and API schemas: Lexicons. It is an ✨Experimental✨ project from the protocol team at Bluesky.
マツモト交商化粧品原材料データベース
This website is provided for cosmetic and pharmaceutical industry professionals who handle cosmetic raw materials.General consumers are not advised to use this site.
ChinaCosIng - Chinese Cosmetic Ingredient Regulatory Database
A model qualification method for mechanistic physiological QSP models to support model‐informed drug development
Mechanistic physiological modeling is a scientific method that combines available data with scientific knowledge and engineering approaches to facilitate better understanding of biological systems, improve decision‐making, reduce risk, and increase efficiency in drug discovery and development. It is a type of quantitative systems pharmacology (QSP) approach that places drug‐specific properties in the context of disease biology. This tutorial provides a broadly applicable model qualification method (MQM) to ensure that mechanistic physiological models are fit for their intended purposes.
Pharmacometrics and systems pharmacology for metabolic bone diseases
Mathematical modelling and simulation (M&S) of drug concentrations, pharmacologic effects and the (patho)physiologic systems within which they interact can be powerful tools for the preclinical, translational and clinical development of drugs. Indeed, the Prescription Drug User Fee Act (PDUFA VI), incorporated as part of the FDA Reauthorization Act of 2017 (FDARA), highlights the goal of advancing model‐informed drug development (MIDD). MIDD can benefit development across many drug classes, including for metabolic bone diseases such as osteoporosis, cancer‐related and numerous rare metabolic bone diseases; conditions characterized by significant morbidity and mortality. A drought looms in terms of the availability of new drugs to better treat these devastating diseases. This review provides an overview of several M&S approaches ranging from simple pharmacokinetic to integrated pharmacometric and systems pharmacology modelling. Examples are included to illustrate the use of these approaches during the development of several drugs for metabolic bone diseases such as bisphosphonates, denosumab, teriparatide and sclerostin inhibitors (romosozumab and blosozumab).
AI for Drug Discovery Needs Trustworthy Biological Data
To unleash the potential of AI in life sciences and drug discovery, biological datasets must be authenticated, validated, and supported by standardized metadata.
OpenMD Medical Reference
Medical reference platform and search engine indexing billions of documents from government agencies, global health organizations, and medical journals.
Notes on Rastair, a variant and methylation caller
In the last year, I’ve had the pleasure to work on Rastair , a bioinformatics project by Benjamin Schuster-Böckler from the Ludwig Institute for Cancer Research at the University of Oxford. It is a …
The Good Scents Company - Cosmetic Ingredients Catalog information
Cosmetic Ingredients Catalog information
Cosmetic Ingredients Master Catalog: all products from all suppliers
Browse the industry's master catalog and find the perfect ingredients for your cosmetic and personal care formulations. Find suppliers. Get samples.